Keywords: cor, gets, partial, ok, integrilin, food, drug
COR Gets Partial OK For Integrilin
Article | 04 February 1998
A US Food and Drug Administration advisory committee has unexpectedlyrecommended Cor Therapeutics' antithrombotic glycoprotein IIb/IIIa receptor antagonist Integrilin (eptifibatide) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
